ASH 2020 | Transposon-manipulated allogeneic CAR-T therapy for B-ALL
Chiara Magnani, MD, Tettamanti Research Center, University of Milano-Bicocca, Monza, Italy, discusses the results of the Phase I/II CARICK trial (NCT03389035) which investigated the use of a non-viral engineered allogeneic T-cell population for CAR T-cell therapy in relapsed B-cell acute lymphoblastic leukemia (B-ALL) patients. Donor-derived CD19 CAR T-cells were generated with the sleeping beauty (SB) transposon and differentiated into cytokine induced killer (CIK) cells (CARCIK-CD19). CARCIK-CD19 was produced successfully for all patients and consisted mostly of CD3+ lymphocytes with a mean of 38.6% CAR expression. The study found that the sleeping beauty-engineered CAR T-cells expanded robustly in most patients, and evidence of persistence was shown for up to 9 months. A highly promising safety profile was noted, allowing sustained responses without severe toxicity in pediatric and adult B-ALL patients after HSCT. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
